Trials / Completed
CompletedNCT05255237
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of Jaktinib in Adult Patients With Moderate to Severe Alopecia Areata
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 315 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study. After completion of ZGJAK018 study, the study will be directly extend with an "open-label design".
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | 75mg BID |
Timeline
- Start date
- 2022-03-25
- Primary completion
- 2024-06-28
- Completion
- 2024-06-28
- First posted
- 2022-02-24
- Last updated
- 2025-03-18
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05255237. Inclusion in this directory is not an endorsement.